Literature DB >> 23599639

Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?

Salvatore D'Angelo, Mario Secondulfo, Raffaele De Cristofano, Paolo Sorrentino.   

Abstract

Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC. In this frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO, on the basis of our practice and published evidence from the literature.

Entities:  

Keywords:  Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Liver function; Sorafenib

Mesh：

Substances：

Year:  2013        PMID： 23599639      PMCID： PMC3627877          DOI： 10.3748/wjg.v19.i14.2141

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  21 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Report of the 16th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Shigeki Arii; Takafumi Ichida; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2005-07-18       Impact factor: 4.288

6.  Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy.

Authors:  Silvia Franceschi; Maurizio Montella; Jerry Polesel; Carlo La Vecchia; Anna Crispo; Luigino Dal Maso; Pietro Casarin; Francesco Izzo; Luigi G Tommasi; Isabelle Chemin; Christian Trépo; Marina Crovatto; Renato Talamini
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-04       Impact factor: 4.254

7.  Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

Authors:  Ju Hyun Shim; Han Chu Lee; Kang Mo Kim; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee; Dong Jin Suh
Journal:  J Hepatol       Date:  2009-12-16       Impact factor: 25.083

Review 8.  Prevention of hepatocellular carcinoma in hepatitis B virus infection.

Authors:  Seng Gee Lim; Rosmawati Mohammed; Man-Fung Yuen; Jia-Horng Kao
Journal:  J Gastroenterol Hepatol       Date:  2009-08       Impact factor: 4.029

Review 9.  Hepatitis virus-related hepatocarcinogenesis.

Authors:  O Hino; K Kajino
Journal:  Intervirology       Date:  1994       Impact factor: 1.763

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  1 in total

Review 1.  The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.

Authors:  Weiwei Tang; Ziyi Chen; Wenling Zhang; Ye Cheng; Betty Zhang; Fan Wu; Qian Wang; Shouju Wang; Dawei Rong; F P Reiter; E N De Toni; Xuehao Wang
Journal:  Signal Transduct Target Ther       Date:  2020-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.